, 1990, Azevedo et al., 2002, Leal and Soares, 2004, Falconer and Humpage, 2005, Andrinolo et al., 2008 and Funari and Testai, 2008). Independently of the exposure route MCYST-LR preferentially reaches the liver and can also be detect in several organs including lungs (Wang et al., 2008). Recently, our group reported the use of an anti-inflammatory Selleck LY2109761 drug candidate, LASSBio 596, to treat the pulmonary damage induced by the acute exposure to MCYST-LR. This compound was designed as an agent that modulates TNF-α and inhibits phosphodiesterases (PDEs) (Lima et al., 2002). Briefly, the intraperitoneal administration of LASSBio 596 avoided most of the pulmonary

structural and functional damages, exhibiting a better outcome than dexamethasone. However, both LY2835219 manufacturer treatments were not effective to avert the liver structural damage (Carvalho et al., 2010). Even though the pharmacokinetics of LASSBio 596 has been described (Rocco et al., 2010), its therapeutic effects on by oral administration are so far unknown. Considering that the intraperitoneal route is not often used in clinical practice and that the treatments did not show effective for liver changes,

an investigation about the therapeutic effects of orally administered LASSBio 596 on pulmonary and hepatic changes seems relevant and could establish the potential of LASSBio 596 as a drug candidate for the treatment of the systemic damage induced by microcystin-LR. Thus, in the present study, we aimed to evaluate the efficacy of LASSBio 596 per os in the treatment of pulmonary and hepatic damage in mice acutely exposed to MCYST-LR. For such purpose pulmonary mechanics, morphology and inflammatory cells influx, as well as the levels of pro-inflammatory mediators both in lungs and liver tissues, were assessed. The present study was approved by the Ethics Committee of the Health Sciences Center, Federal University

of Rio de Janeiro (Protocol IBCCF 012). All animals received humane care according to the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” by the National Academy of Sciences, USA. Twenty-six Swiss mice (35–40 g) were purchased from the animal facilities of the University of Campinas (CMIB/UNICAMP). They were randomly divided MycoClean Mycoplasma Removal Kit into 3 groups: In the control group, 40 μl of sterile saline solution (0.9% NaCl, CTRL, n = 8) were intraperitoneally (i.p.) injected, whereas in the other two groups a sub-lethal dose of MCYST-LR (40 μg/kg i.p., purified material kindly provided by Professor Wayne Carmichael, Wright State University, Dayton, OH, USA) was administered. After 6 h, CTRL, TOX (n = 8), and LASS (n = 10) mice received per os 60 μl of a solution composed by 57.5 μl of sterile saline and 2.5 μl of dimethyl sulfoxide (DMSO); in the latter group the solution contained 50 mg/kg of LASSBio 596.